A102940 Stock Overview
A biotechnology company, develops cell and gene therapy products. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Kolon Life Science Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩23,800.00 |
| 52 Week High | ₩31,000.00 |
| 52 Week Low | ₩16,780.00 |
| Beta | 0.35 |
| 1 Month Change | 32.22% |
| 3 Month Change | 25.79% |
| 1 Year Change | -4.80% |
| 3 Year Change | -37.53% |
| 5 Year Change | 31.86% |
| Change since IPO | -12.49% |
Recent News & Updates
Recent updates
There's Reason For Concern Over Kolon Life Science Inc.'s (KOSDAQ:102940) Massive 45% Price Jump
Dec 13
Risks Still Elevated At These Prices As Kolon Life Science Inc. (KOSDAQ:102940) Shares Dive 26%
Mar 02We Think Kolon Life Science (KOSDAQ:102940) Has A Fair Chunk Of Debt
Mar 12A Look At Kolon Life Science's (KOSDAQ:102940) Share Price Returns
Jan 18Kolon Life Science (KOSDAQ:102940) Is Carrying A Fair Bit Of Debt
Nov 26
Shareholder Returns
| A102940 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 4.4% | -0.5% | -1.9% |
| 1Y | -4.8% | 0.8% | -9.5% |
Return vs Industry: A102940 underperformed the KR Pharmaceuticals industry which returned 2.4% over the past year.
Return vs Market: A102940 exceeded the KR Market which returned -9% over the past year.
Price Volatility
| A102940 volatility | |
|---|---|
| A102940 Average Weekly Movement | 8.3% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.8% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A102940 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A102940's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 420 | Sun Jin Kim | www.kolonls.co.kr |
Kolon Life Science Inc., a biotechnology company, develops cell and gene therapy products. The company is developing KLS-2031, a product candidate in Phase 1 clinical trials for use in the treatment of neuropathic pain; and KLS-3021, a oncolytic viral therapy in pre-clinical development. It also provides active pharmaceutical ingredients and pharmaceutical intermediates; offers CDMO and CMO services; and supplies pyrithione antimicrobial for use in personal care and industrials products.
Kolon Life Science Inc. Fundamentals Summary
| A102940 fundamental statistics | |
|---|---|
| Market cap | ₩295.68b |
| Earnings (TTM) | -₩89.71b |
| Revenue (TTM) | ₩147.98b |
2.0x
P/S Ratio-3.3x
P/E RatioIs A102940 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A102940 income statement (TTM) | |
|---|---|
| Revenue | ₩147.98b |
| Cost of Revenue | ₩138.01b |
| Gross Profit | ₩9.97b |
| Other Expenses | ₩99.68b |
| Earnings | -₩89.71b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.22k |
| Gross Margin | 6.74% |
| Net Profit Margin | -60.63% |
| Debt/Equity Ratio | 97.5% |
How did A102940 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 02:39 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kolon Life Science Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| JooYong Kim | Bookook Securities Co. Ltd |
| Bora Chung | Daishin Securities Co. Ltd. |
| Ha Young Kang | DAOL Investment & Securities Co., Ltd. |